Table 2.
Subject | FVCRelax, min−1 ⋅ 100 mmHg−1 | FVCRelax, P | FBF, ml/min | FBF, P |
---|---|---|---|---|
Placebo, n = 6 | ||||
E | 556 vs. 547 | 0.23 | 338 vs. 313 | 0.06 |
H | 987 vs. 988 | 0.46 | 667 vs. 506 | 3.61E-03 |
O | 630 vs. 640 | 0.56 | 366 vs. 329 | 0.10 |
R | 520 vs. 532 | 0.60 | 290 vs. 207 | 9.88E-04 |
U | 777 vs. 786 | 0.42 | 401 vs. 380 | 0.16 |
W | 686 vs. 681 | 1.00 | 435 vs. 376 | 1.3E-03 |
Average ± SD | 688 ± 166 vs. 697 ± 171 | 0.42 | 415 ± 131 vs. 353 ± 98* | 0.03 |
Nitrate, n = 6 | ||||
E | 543 vs. 647 | 1.54E-05 | 350 vs. 353 | 0.87 |
H | 758 vs. 898 | 1.35E-06 | 437 vs. 406 | 0.07 |
O | 478 vs. 557 | 6.55E-05 | 316 vs. 324 | 0.25 |
R | 431 vs. 604 | 3.40E-07 | 221 vs. 246 | 0.03 |
U | 545 vs. 855 | 6.37E-05 | 308 vs. 335 | 5.33E-03 |
W | 643 vs. 713 | 0.02 | 396 vs. 383 | 0.35 |
Average ± SD | 568 ± 117 vs. 714 ± 139* | 5.0E-03 | 338 ± 71 vs. 341 ± 55 | 0.69 |
Values presented for each participant are the means of the 3 trials. E-03–E-07, exponents to negative 3–7, respectively.
Statistical significant difference between reduced perfusion pressure and control perfusion pressure positions (P < 0.05).